Higher insulin resistance index was significantly associated with long-term in-stent restenosis after coronary drug-eluting stent implantation (adjusted OR 1.476; 95% CI 1.227-1.776; P<0.001).
Cohort (n=529)
No
Does insulin resistance increase the risk of in-stent restenosis in patients undergoing coronary DES implantation?
Insulin resistance is an independent predictor of long-term in-stent restenosis following drug-eluting stent implantation, including in non-diabetic patients.
Effect estimate: OR 1.476 (95% CI 1.227-1.776)
p-value: p=<0.001
OBJECTIVE: Previous studies have reported that insulin resistance is related to early in-stent restenosis (ISR) after coronary stenting. This study aimed to evaluate the influence of insulin resistance on the long-term angiographic outcome in patients undergoing coronary drug-eluting stent (DES) implantation. MATERIALS AND METHODS: Within a single hospital-based cohort of patients (n=529) who underwent coronary DES implantation, angiographic follow-up was performed successfully for 417 study patients at 12-48 months after coronary stenting. ISR was defined as stenosis of at least 50% of the luminal diameter. Fasting plasma glucose and fasting plasma insulin were measured. Insulin resistance was expressed by the homeostasis model assessment index (HOMA-IRI). RESULTS: Among the 417 patients who completed angiographic follow-up (mean 17.5±10.2 months), 58 patients (13.9%) had ISR whereas the remaining 359 patients (86.1%) did not have ISR. Patients with ISR had higher insulin resistance index (IRI) than nonrestenosis patients (P=0.004). Multiple logistic regression analysis (logit) showed that IRI was associated significantly with ISR (adjusted odds ratio 1.476, 95% confidence interval 1.227-1.776; P<0.001). In the nondiabetes subgroup of 309 patients, IRI was higher in patients with ISR than in nonrestenosis patients, as confirmed in a separate logit analysis (adjusted odds ratio 1.456, 95% confidence interval 1.152-1.839; P=0.002). Multiple linear regression analysis showed that IRI was associated significantly with in-stent diameter stenosis degree (P=0.043). CONCLUSION: Insulin resistance was associated with ISR in patients undergoing coronary DES implantation at long-term angiographic follow-up.
Zhao et al. (Thu,) conducted a cohort in Coronary drug-eluting stent (DES) implantation (n=529). Insulin resistance (HOMA-IRI) vs. Lower insulin resistance was evaluated on In-stent restenosis (ISR) defined as stenosis of at least 50% of the luminal diameter (OR 1.476, 95% CI 1.227-1.776, p=<0.001). Higher insulin resistance index was significantly associated with long-term in-stent restenosis after coronary drug-eluting stent implantation (adjusted OR 1.476; 95% CI 1.227-1.776; P<0.001).